Nextech Ar Solutions

Nextech Invest disclosed it sold 62,013 shares of Kymera Therapeutics in Q4 in a transaction estimated at $4.19 million, leaving a post‑trade holding of 278,896 shares valued at $21.70 million as of Dec. 31, 2025. The position now represents 2.1% of the fund’s 13F reportable AUM and falls outside its top five holdings. Despite the sales, the quarter‑end position value rose by $2.41 million due to Kymera’s price appreciation; the move is characterized as a trim rather than an exit amid a concentrated portfolio strategy. » Más en finance.yahoo.com